Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

Dow Jones

Jan 29, 2025

By Dean Seal

Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter.

The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago.

Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share.

Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet.

Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor.

Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%.

For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

January 29, 2025 06:29 ET (11:29 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507253684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507253684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507253684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507253684","market":"other","top_or_hot":-1,"title":"Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter. \n</p>\n<p>\n  The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share. \n</p>\n<p>\n  Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet. \n</p>\n<p>\n  Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor. \n</p>\n<p>\n  Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%. \n</p>\n<p>\n  For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2025 06:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDanaher 4Q Revenue Rises on Gains in Life Sciences, Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-29 19:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter. \n</p>\n<p>\n  The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share. \n</p>\n<p>\n  Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet. \n</p>\n<p>\n  Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor. \n</p>\n<p>\n  Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%. \n</p>\n<p>\n  For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2025 06:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DHR","symbol_name":"丹纳赫","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2507253684","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507253684","pubTimestamp":1738150140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter.The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago.Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share.Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet.Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor.Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%.For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DHR":"丹纳赫"},"translate_title":"丹纳赫第四季度收入因生命科学和生物技术领域的增长而增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1},"content_text":"By Dean Seal \n\n\n \n\n\n  Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter. \n\n\n  The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago. \n\n\n  Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share. \n\n\n  Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet. \n\n\n  Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor. \n\n\n  Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%. \n\n\n  For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2025 06:29 ET (11:29 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}